<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The monoclonal antibodies M195 and HuM195 target CD33, a <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> found on myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="1" pm="."><plain>When labeled with <z:chebi fb="60" ids="24859">iodine</z:chebi>-131 ((131)I), these antibodies can eliminate large disease burdens and produce prolonged <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We studied whether (131)I-labeled M195 and HuM195 could be combined safely with <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (BuCy) as conditioning for allogeneic BMT </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 31 patients with relapsed/refractory <z:hpo ids='HP_0011009'>acute</z:hpo> myeloloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) (n=16), accelerated/myeloblastic <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) (n=14), or advanced <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=1) received (131)I-M195 or (131)I-HuM195 (122-437 mCi) plus <z:chebi fb="0" ids="28901">busulfan</z:chebi> (16 mg/kg) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (90-120 mg/kg) followed by infusion of related-donor bone marrow (27 first BMT; four second BMT) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0002904'>Hyperbilirubinemia</z:hpo> was the most common extramedullary toxicity, occurring in 69% of patients during the first 28 days after BMT </plain></SENT>
<SENT sid="5" pm="."><plain>Gamma camera imaging showed targeting of the radioisotope to the bone marrow, liver, and spleen, with absorbed radiation doses to the marrow of 272-1470 cGy </plain></SENT>
<SENT sid="6" pm="."><plain>The median survival was 4.9 months (range 0.3-90+ months) </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> remain in complete remission 59+, 87+, and 90+ months following bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="8" pm="."><plain>These studies show the feasibility of adding CD33-targeted radioimmunotherapy to a standard BMT preparative regimen; however, randomized trials will be needed to prove a benefit to intensified conditioning with radioimmunotherapy </plain></SENT>
</text></document>